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Abstract 
Objective. Observational data facilitate examination of treatment-effect heterogeneity, but the risk 
of bias is substantial. We highlight methodological considerations through an analysis of whether 
smoking affects response to TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA). 
Methods. We used longitudinal data from the British Society for Rheumatology Biologics Register for 
Ankylosing Spondylitis. Participants fulfilling the ASAS criteria for axSpA, who started their first TNFi 
were eligible for analysis. To compare the impact of smoking status, weighted generalised estimating 
equations were used to examine changes in several continuous outcome measures, including 
BASDAI and ASDAS. Inverse-probability weights were used to account for differences in baseline 
covariates and excluded participants. We separately assessed response in the first 3 months to 
account for non-random dropout. 
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Results. Of 840 participants that started on TNFi, 1,641 assessments from 627 individuals were 
analysed (69% male, mean age 46 years). 33% were current smokers and 30% ex-smokers. Ex- and 
current smokers had worse disease than never smokers at baseline. Accounting for these 
differences, response did not differ according to smoking status. Compared against never smokers, 
ex-smokers (β=-0.6; 95%CI -1.4, 0.3) and current smokers (β=-0.4; 95%CI -1.1, 0.4) had similar 
response in BASDAI, and ASDAS (ex: β=-0.1; 95%CI -0.5, 0.3; current: β=-0.01; 95%CI -0.4, 0.4), at 3 
months. 
Conclusions. TNFi response did not differ according to baseline smoking status in this UK cohort. 
Conflicting results from previous studies were likely due to methodological differences. This analysis 
highlights potential sources of bias that should be addressed in future studies. 
Keywords: axial spondyloarthritis, ankylosing spondylitis, registry, treatment response, inverse 
probability weights 
 
Key messages:  
 Observational studies are susceptible to bias and potential sources should be identified and 
addressed. 
 Conflicting results from prior studies are likely explained by methodological differences. 
 Response to TNF inhibitors did not differ according to smoking status in this large cohort. 
 
Introduction 
Disease registries are important resources for observational research. They provide high quality data 
for large numbers of patients generalisable to clinical practice, making them invaluable for 
comparing effectiveness of treatments. However, observational data are susceptible to bias, 
requiring rigorous methodological approaches when attempting to infer causation. Consider the 
effect of smoking on response to TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA): an 
important clinical question since only half of patients respond (1, 2) and alternative treatment 
options are relatively limited. While some smaller studies reported that smoking did not have an 
important impact on TNFi response (3-5), others found apparently dramatic effect sizes with current 
smokers having half the odds of response compared to non-smokers (6, 7). 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Several methodological differences may explain these conflicting results. First, many patient 
characteristics differ according to smoking status (3, 6, 7). Baseline disease severity is known to 
predict response to TNFi and should be adequately accounted for. Second, longitudinal studies apply 
selection criteria that typically exclude a proportion of participants from the analysis set, for 
example by requiring at least one follow-up visit. Such sample-restriction introduces selection bias if 
included and excluded participants differ in smoking status and other baseline characteristics. Third, 
continuation of TNFi typically requires demonstration of response, with variable enforcement and 
response definitions in different healthcare systems. Ongoing treatment in the UK is only funded if 
response is demonstrated at 12 weeks (allowing for some flexibility) as measured by the Bath AS 
Disease Activity Index (BASDAI) and spinal pain (8, 9). Dropout due to inefficacy or adverse events 
are examples of non-random censoring (ie. these events are associated with participant 
characteristics) that can present problems for observational analyses (10). 
The aim of the current analyses was to examine the impact of smoking on response to TNFi in axSpA 
participants, while exploring common methodological issues and their solutions. We synthesise our 
discussion alongside a qualitative review of methods and results from existing studies. 
 
Methods 
Study design and population 
The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) is a 
UK-wide prospective cohort study of participants fulfilling the ASAS criteria for axSpA. The study 
protocol has been previously published (11). The current analysis focused on those who started their 
first TNFi, from December 2012 to June 2017. These participants were followed up at baseline, 3, 6 
and 12 months and annually thereafter, at study visits and using postal questionnaires. Start and 
stop dates were recorded for each TNFi, along with the reason for stopping (adverse events, 
inefficacy or other reasons). The cohort was defined at baseline, therefore only those with a valid 
baseline questionnaire (within 1 year before and 7 days after starting TNFi) and had smoking status 
were eligible for analysis. Where there was more than one questionnaire in each time period, the 
nearest one to the per-protocol follow-up time was chosen. Ethical approval was obtained from the 
National Research Ethics Committee (reference 11/NE/0374) and informed consent was obtained 
from all participants. 
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Exposure and outcomes 
Smoking status was self-reported as current, ex- or never in each questionnaire. Baseline smoking 
status was used to define the exposure; where this was missing, the earliest reported instance was 
used. Ex-smokers were defined as those who have not smoked for the past 3 months. 
Outcomes included patient-reported disease activity (Bath AS Disease Activity Index (BASDAI), spinal 
pain), functional impairment (BASFI) and other aspects of disease severity such as the Bath AS Global 
Score (BASG), Chalder Fatigue Scale (12), Jenkins Sleep Evaluation Questionnaire (13) and the 
Hospital Anxiety and Depression Scale (HADS) (14). The AS Disease Activity Score (ASDAS) was 
calculated using CRP or, if unavailable, ESR. 
We compared changes in outcomes (measured by the above scales) over time to their pre-treatment 
baseline, between difference categories of smokers. To allow comparison with existing studies, we 
also compared proportions meeting a binary response, BASDAI50/2 (50% or 2-unit reduction in 
BASDAI) at 3, 6 and 12 months. 
 
Covariates 
The following covariates were recorded at baseline and chosen a priori for their known or 
theoretical associations with TNFi response (1, 2, 15-17): age, gender, symptom duration, education, 
elevated baseline CRP (above upper normal limit), classification as AS (modified New York criteria 
(18)), HLA-B27 status, body mass index (BMI), index of multiple deprivation (in quintiles (19-21)) as a 
measure of socioeconomic status, alcohol status (as current, ex- or never) and comorbidity 
(categorised as 0, 1 or ≥2 from 13 conditions (11)). Time was categorised by per-protocol follow-up. 
Statistical analysis 
Baseline participant characteristics were summarised by smoking status. For each outcome variable, 
we compared its change over time according to smoking status using generalised estimating 
equations (GEE) (22). This was achieved using interaction terms between smoking status and the 
time variable: their coefficients are interpreted as the difference in response compared to the 
reference group (never smokers). Model predictions were plotted to visualise results. These models 
were weighted with weights constructed as follows. 
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We balanced differences in baseline characteristics between smoking exposure categories using 
inverse probability of “treatment” weights (IPTW) (23). This adjustment approach has an advantage 
over inclusion of the baseline characteristics in the outcome model (the theoretical basis is given in 
supplementary materials). A multinomial logistic model was used to construct IPTW for each 
smoking category. Independent variables for the weight model included all baseline covariates 
specified above as well as all baseline outcome measures (as a collective representation of disease 
severity). Studying the causal effect of baseline smoking status has conceptual difficulty: we cannot 
randomly assign an individual to “having smoked for 20 years” at the onset of a hypothetical trial 
(24). However, propensity score related methods are still useful for “unconfounded descriptive 
comparisons” (25, 26). 
Including participants with a baseline questionnaire assumes this selected subset is representative of 
the initial cohort. We improved upon this approach by weighting individuals in such a way that 
baseline characteristics of the analysis set resembles the original eligible cohort. This is a form of 
inverse probability of censoring weights (IPCW) for censoring at the baseline. IPCWs were 
constructed from predicted values of logistic models using inclusion/exclusion status as the 
dependent variable, and smoking status and available baseline covariates as independent variables.  
To address informative censoring after the baseline, we first limited the above analysis to response 
within 3 months (analysis 1), during which time dropout due to inefficacy should be minimal. Missing 
3-month responses were modelled using time-varying IPCWs as described above with “missingness” 
as the dependent variable. This makes missingness random with respect to baseline characteristics. 
We then repeated the analysis for the subset of participants that remained on treatment from 6 
months onwards (analysis 2) using baseline IPCWs to account for the excluded, as described above, 
but without additional use of time-varying IPCWs. 
Lastly, BASDAI50/2 was used as the outcome in weighted logistic models. Dropout due to inefficacy 
was defined as non-response; other missing responses were modelled using IPCWs as described 
above. All weights were “stabilised” to have a mean of 1, allowing the overall sample size to remain 
unchanged (27). Missing covariates were imputed using chained equations (see supplement for 
details) (28). Analyses were performed in Stata version 13. 
Results 
Among a total of 2,420 participants in the BSRBR-AS, 840 commenced their first TNFi within the 
study period and provided smoking status. 213 participants were excluded because they did not 
have a valid baseline assessment. 627 participants were included in analyses, providing 1,641 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
questionnaire assessments. Excluded participants had shorter symptom duration and showed trends 
for having lower deprivation and higher educational attainment (differences shown in 
supplementary table 1). 
 
Analysis 1: Comparing response at 3 months according to smoking status 
Baseline characteristics of the analysis cohort are shown in table 1. Covariate were well balanced 
after IP weighting (supplementary figure 1). A third of participants were current smokers, 30% ex-
smokers and 37% never smokers. Current smokers were younger, more frequently male and showed 
trends for having higher deprivation and lower educational attainment. Baseline values of most 
outcome variables were worse in ex- and current smokers. 218 participants had missing outcome 
measures at 3 months and were modelled using IPCWs; the number of participants who stopped 
their TNFi during this period was too small (n=1) to model separately. 
All outcomes improved significantly after commencing TNFi. These changes were highly similar for 
each smoking status (BASDAI and BASFI shown in figure 1, remainder shown in supplementary figure 
2). Although not statistically significant, interaction term coefficients suggest that BASDAI reduction 
at 3 months was greater for ex- (β= -0.58; 95%CI -1.41 to 0.25) and current smokers (β= -0.38; 
95%CI-1.12 to 0.36) compared to never smokers (table 2). Results were similar for most other 
outcome measures, except ex-smokers had significantly greater improvement in fatigue. 
Analysis 2: Comparing response after 6 months in those who remained on treatment 
During the study period, 136 participants discontinued treatment: adverse event was labelled as the 
reasons for 49, inefficacy for 32 and other for 55. Proportions were not significantly different 
according to smoking status (table 1). Baseline characteristics for participants in analysis 2 are shown 
in supplementary table 2. 
Progression of outcome measures after 6 months were similar between each smoking status (table 
3). Compared to never smokers, BASDAI increased by 0.07 units more (95%CI -0.11 to 0.24) for ex-
smokers and 0.04 units more (95%CI -0.13 to 0.22) for current smokers, per 6-month period. The 
only statistically significant differences were for fatigue and ASDAS. The slope coefficients suggest 
that current smokers may have poorer sustained treatment response after 6 months than never 
smokers (figure 2 and supplementary figure 3). 
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BASDAI50/2 response at 3 months was not significantly different for ex-smokers (OR 1.11; 95%CI 
0.76 to 1.61) or current smokers (OR 0.97; 95%CI 0.66 to 1.44), compared with never smokers. 
Results were similar at 6 months (ex-smokers: OR 1.01, 95%CI 0.67 to 1.50; current smokers: OR 
0.85, 95%CI 0.56 to 1.27). At 12 months, ex-smokers had higher odds of response (OR 1.65, 95%CI 
1.11 to 2.45), but not current smokers (OR 1.12, 95%CI 0.74 to 1.77). Distributions of all IP weights 
are described in supplementary table 3. 
 
Discussion 
In this large UK cohort of axSpA participants, baseline smoking status was associated with 
significantly worse disease severity at baseline across all measures. However, it was not associated 
with response to the first TNFi. This applied to all outcome measures including disease activity, 
functional impairment, quality of life, fatigue, sleep and mental health. We demonstrated the 
importance of several methodological considerations for future studies of non-interventional 
exposures on treatment response, and offer inverse-probability weighting as a solution to reduce 
potential bias. 
The main strength of this study is the quality of data. Several outcomes were measured that provide 
a holistic representation of disease severity and impact. The rich BSRBR-AS dataset also allowed us 
to adjust for a large number of confounders, minimising the impact of unmeasured confounding. 
Participants were recruited from both specialist and non-specialist secondary care centres, thus 
providing a relatively unselected population representative of UK clinical practice.  
Our data did have some limitations. There was an unusually low proportion of discontinuation due 
to inefficacy, likely reflecting limitations in the way discontinuation reasons were labelled. However, 
the start and stop dates for each TNFi were diligently recorded, providing clear information about 
duration of use. The BSRBR-AS did not record exercise or other lifestyle factors that are potential 
confounders. We did adjust for socioeconomic status, and included alcohol-use as another 
representation of health-related behaviour; exercise did not contribute significant confounding in a 
previous study (6). We did not examine BASMI, ESR or CRP as these variables required a clinic visit, 
which made them distinct from questionnaire-derived variables that would require separate 
modelling. ESR/CRP were also different in that they were measured only when clinically indicated. 
Subtle differences between smoking status for some outcomes were not clinically important and 
should not be over-interpreted. It was interesting that current and ex-smokers had non-significantly 
greater improvement in analysis 1, which may be explained by regression towards the mean. Higher 
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odds of 12-month response in ex-smokers may be explained by the fact that people who give up 
smoking might also make other healthy decisions. 
Results from three similar studies are summarised in table 4. The first, by Ciurea et al., used mixed 
models to show a statistically significant, but not clinically important, effect of smoking only among a 
subgroup of those with elevated baseline CRP (6). Their “step model” of initial response was 
analogous to analysis 1 in our study. The main difference was that patients needed to have at least 
one follow-up to be eligible. Conditioning on follow-up attendance is likely to introduce bias (29). 
The study by Kydd et al. used linear mixed models to include individuals with only one data-point: 
the maximum number of patients at any assessment period was 252 despite a total sample size of 
422. Only 99 patients had their outcomes of interest assessed before initiating TNFi, therefore 
making it difficult to adjust for baseline differences. In that study, the interaction terms, 
representing the difference in outcomes between smoking status, were not significant. 
Previous studies that used binary definitions of response reported dramatic effect sizes related to 
current smoking (6, 7). The study by Ciurea et al., which found no clinically meaningful overall 
difference in continuous BASDAI according to smoking status, reported 46% reduced odds for 
achieving BASDAI50 response (OR 0.54; 95%CI 0.31 to 0.95) at 1 year (±6 months) (6). This was 
reproduced by Glintborg et al. using BASDAI50/2 at 3 and 6 months (7). Small changes in continuous 
outcomes should not translate to significant differences in the proportion of responders when they 
are dichotomised. There are two potential explanations. If all patients had identical improvements in 
BASDAI, smokers would still have poorer BASDAI50 response because of their higher baseline 
BASDAI. Hypothetically, if each participant in our cohort improved by an identical 3 units, their 
BASDAI50 responses at 6 months would be significantly different (40%, 35% and 28% for never, ex- 
and current smokers, respectively). Second, patients who discontinued treatment were labelled as 
non-responders. Whether smoking has a biological effect on response is a different question to 
whether it increases treatment discontinuation, yet this distinction is crucial for causal inference. 
Smokers may discontinue treatment for reasons other than inefficacy that may be confounded by, 
for instance, attitudes to health. While binary responses can be helpful in including dropout due to 
inefficacy, other reasons for dropout should be modelled separately. In the current study, smoking 
did not affect BASDAI50/2 when we separately accounted for subjects who were censored for 
reasons other than inefficacy. These negative results were supported by a post hoc analysis of the 
ABILITY-1 randomised clinical trial, where smoking status did not affect binary response or time to 
response (5). 
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Conclusion 
We used this analysis to highlight methodological considerations for future observational studies 
aiming to explore causal effects of exposures on treatment response. In this large UK cohort of 
axSpA participants, response to the first TNFi did not differ significantly according to baseline 
smoking status. Prescribers should dispel any subconscious bias that smokers may not respond as 
well to treatment. Nevertheless, we emphasise the importance of smoking cessation, particularly 
given the high burden of cardiovascular disease in rheumatic patients (30, 31). Smoking is associated 
with more severe disease (activity, functional impairment and radiographic progression (32)); it is 
not known whether cessation leads to improvement in disease outcome.  
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Figure 1. No statistically significant difference in BASDAI and BASFI response to TNF inhibitors at 3 
months according to smoking status. Plots show predicted values from weighted generalised 
estimating equations. Responses using the remaining eight outcome measures were similar and are 
shown in supplementary figure 2. 
 Figure 2. No significant difference in response to TNF inhibitors after 6 months according to smoking 
status. Plots show predicted values from weighted generalised estimating equations. Responses 
using the remaining eight outcome measures were similar and are shown in supplementary figure 3. 
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Table 1. Baseline participant and disease characteristics according to smoking status. 
 Never smoker 
(n=234) 
Ex-smoker 
(n=187) 
Current 
smoker 
(n=206) 
P-value 
Age, mean (SD) years 45.0 (14.9) 50.0 (13.2) 42.3 (12.2) <0.001 
Male 153 (65%) 121 (65%) 156 (76%) 0.027 
Meets mNY criteria for AS 143 (61%) 123 (66%) 123 (60%) 0.440 
HLA-B27 positive+ 127 (71%) 102 (77%) 125 (81%) 0.122 
Elevated CRP* 133 (58%) 108 (61%) 129 (66%) 0.221 
Symptom duration, median (IQR) 
years 
15.0 (5.4 to 
29.3) 
20.8 (10.5 to 
32.8) 
13.1 (5.6 to 
23.6) 
<0.001 
BMI, mean (SD) 27.7 (5.8) 28.9 (5.0) 27.5 (5.7) 0.038 
Quintiles of 
Index of 
Multiple 
Deprivation 
1, most deprived 36 (15%) 29 (16%) 67 (33%) <0.001** 
2 48 (21%) 23 (12%) 35 (17%) 
3 39 (17%) 39 (21%) 40 (19%) 
4 64 (27%) 48 (26%) 37 (18%) 
5, most affluent 47 (20%) 48 (26%) 27 (13%) 
Highest level 
of education 
Secondary school 70 (30%) 60 (32%) 95 (47%) <0.001 
Apprenticeship 16 (7%) 22 (12%) 24 (12%) 
Further education 
college 
68 (29%) 68 (37%) 55 (27%) 
University degree 60 (26%) 30 (16%) 22 (11%) 
Further degree 18 (8%) 5 (3%) 6 (3%) 
Alcohol status Current 179 (77%) 147 (79%) 130 (63%) 0.001 
Ex 32 (14%) 31 (17%) 50 (24%) 
Never 22 (9%) 9 (5%) 26 (13%) 
Number of 
comorbidities 
0 140 (60%) 94 (51%) 105 (51%) 0.055** 
1 63 (27%) 53 (29%) 67 (33%) 
≥2 29 (13%) 38 (21%) 34 (17%) 
Disease 
activity, 
median (IQR) 
BASDAI 6.4 (5.1 to 7.4) 6.8 (5.5 to 8.1) 7.2 (5.9 to 7.9) 0.004 
ASDAS+ 2.9 (2.4 to 3.4) 3.0 (2.4 to 3.5) 3.0 (2.6 to 3.6) 0.042 
Spinal pain 7.0 (5.0 to 8.0) 7.0 (5.0 to 8.0) 7.0 (6.0 to 8.0) 0.028 
BASFI, median (IQR) 6.0 (4.1 to 7.7) 6.7 (5.0 to 8.3) 7.1 (5.5 to 8.5) <0.001 
ASQoL, median (IQR) 11.0 (8.0 to 
14.0) 
13.0 (9.0 to 
16.0) 
15.0 (11.0 to 
17.0) 
<0.001 
BASG+, median (IQR) 7.5 (6.0 to 8.0) 7.5 (6.0 to 8.5) 7.5 (6.3 to 8.5) 0.170 
Fatigue, median (IQR) 17.0 (14.0 to 
21.0) 
17.0 (13.0 to 
21.0) 
18.0 (14.0 to 
22.0) 
0.390 
Sleep, median (IQR) 13.0 (8.0 to 
17.0) 
15.0 (9.0 to 
18.0) 
15.0 (11.0 to 
19.0) 
0.004 
HADS, 
median (IQR) 
Anxiety 8.0 (5.0 to 
11.0) 
8.5 (6.0 to 
11.0) 
11.0 (8.0 to 
14.0) 
<0.001 
Depression 6.0 (3.0 to 9.0) 7.5 (5.0 to 
10.0) 
9.0 (6.0 to 
12.0) 
<0.001 
Remained on treatment 188 (80%) 149 (80%) 154 (75%) 0.230 
Stopped 
treatment 
Adverse events 20 (9%) 16 (9%) 13 (6%) 
Inefficacy 11 (5%) 6 (3%) 15 (7%) 
Other 15 (6%) 16 (9%) 24 (12%) 
Data presented as mean (standard deviation), median (interquartile range), number (percentage). 
Comparisons used ANOVA or Kruskal–Wallis test for continuous variables, Chi-squared test for 
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categorical variables. 
+ Not all variables had complete data, HLA-B27 status was available for 468 participants, ASDAS for 
539. 
*Above upper normal limit. 
**Non-parametric test for trend across ordered groups. 
SD, standard deviation; IQR, interquartile range; mNY, modified New York criteria for Ankylosing 
Spondylitis; BMI, body mass index; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity 
score; BASFI, Bath AS functional index; ASQoL, AS quality of life questionnaire; BASG, Bath AS Global 
Score; HADS, Hospital Anxiety and Depression Scale. 
  
 
 
 
 
Table 2. Coefficients of interaction terms between smoking status and time, showing 
the difference in 3-month response compared to never smokers (analysis 1). 
  Never 
smoker 
Ex-smoker Current smoker 
Disease 
activity 
BASDAI reference -0.58 (-1.41 to 0.25) -0.38 (-1.12 to 0.36) 
ASDAS reference -0.07 (-0.47 to 0.32) -0.01 (-0.42 to 0.40) 
Spinal pain reference -0.67 (-1.61 to 0.26) -0.36 (-1.32 to 0.60) 
BASFI reference -0.59 (-1.40 to 0.22) 0.21 (-0.61 to 1.03) 
ASQoL reference -1.56 (-3.20 to 0.09) -0.34 (-1.94 to 1.26) 
BASG reference -0.61 (-1.29 to 0.08) -0.13 (-0.84 to 0.58) 
Fatigue reference -2.29 (-4.29 to -0.28) -0.64 (-2.73 to 1.44) 
Sleep reference 0.22 (-1.82 to 2.25) 0.67 (-1.29 to 2.63) 
HADS Anxiety reference -0.38 (-1.58 to 0.82) -0.37 (-1.87 to 1.14) 
Depression reference -0.90 (-2.14 to 0.34) -0.41 (-1.76 to 0.94) 
Example interpretation of coefficients: ex-smokers had an additional 0.58-unit 
reduction in BASDAI compared to never smokers at 3 months. 
BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath 
AS functional index; ASQoL, AS quality of life questionnaire; BASG, Bath AS Global 
Score; HADS, Hospital Anxiety and Depression Scale. 
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Table 3. Coefficients of interaction terms between smoking status and time, showing 
the difference responses after 6 months, compared to never smokers (analysis 2).  
  Never 
smoker 
Ex-smoker Current smoker 
Disease 
activity 
BASDAI reference 0.07 (-0.11 to 0.24) 0.04 (-0.13 to 0.22) 
ASDAS reference 0.02 (-0.10 to 0.13) 0.10 (0.002 to 0.20) 
Spinal pain reference -0.01 (-0.28 to 0.26) 0.17 (-0.05 to 0.38) 
BASFI reference 0.03 (-0.18 to 0.23) 0.02 (-0.19 to 0.23) 
ASQoL reference 0.28 (-0.11 to 0.67) 0.27 (-0.12 to 0.66) 
BASG reference 0.17 (-0.08 to 0.42) 0.17 (-0.08 to 0.42) 
Fatigue reference 0.49 (0.05 to 0.93) 0.46 (0.03 to 0.90) 
Sleep reference 0.26 (-0.17 to 0.70) 0.26 (-0.17 to 0.69) 
HADS Anxiety reference 0.14 (-0.11 to 0.39) -0.10 (-0.42 to 0.23) 
Depression reference 0.08 (-0.15 to 0.31) 0.16 (-0.17 to 0.50) 
Coefficients shown for time in units of 6 months. 
Example interpretation of coefficients: BASDAI in ex-smokers worsened by 0.07 units 
more than never smokers per 6-month period. 
BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath 
AS functional index; ASQoL, AS quality of life questionnaire; BASG, Bath AS Global 
Score; HADS, Hospital Anxiety and Depression Scale. 
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Table 4. Comparing published studies of the effect of smoking on response to TNFi. 
 Ciurea 2015 Glintborg 2015 Kydd 2015 This study 
Cohort and 
analysis set 
Swiss Clinical Quality Management 
Cohort (n=2973) 
 
1880 fulfilled ASAS criteria with 
available smoking status. 
698 eligible for analysis with at least 
one follow-up assessment. 
DANBIO (n=1775) 
 
1576 were eligible for inclusion. 
1425 eligible for analysis with 
known smoking status. 
Australian Rheumatology 
Association Database 
(n=561) 
 
422 eligible with at least one 
assessment within 27 
months of starting TNFi. 
BSRBR-AS (n=2420) 
 
947 exposed to first TNFi. 
628 eligible for analysis with baseline 
assessment (excluded participants 
accounted for using IPCW). 
Baseline 
characteristics 
Mean BASDAI 5.5 (SD 1.9) 
 
Significant differences according to 
smoking status: BASFI, BASMI, EQ5D, 
SF-12, elevated CRP; age, gender, 
education.  
Median BASDAI 5.6 to 6.1 
 
Significant differences according to 
smoking status: CRP, BASDAI, 
BASFI, BASMI, pain and 
physician/patient global; age, 
disease duration, gender. 
Mean BASDAI 7.3 (SD 1.5) 
 
Significant differences 
according to smoking status: 
SF-36, AQoL; age, gender, 
disease duration, education.  
Mean BASDAI 6.3 (SD 1.8), median 6.6 
 
Significant differences according to 
smoking status: BASDAI, ASDAS, 
BASFI, BASMI, ASQoL, JSEQ, HADS; 
age, gender, symptom duration, BMI, 
deprivation, education, alcohol 
Exposure  38% current, 24% ex, 38% never 43% current, 16% ex ,41% never 
 
19% current, 33% ex, 49% 
never 
 
29% current, 32% ex, 39% never 
 
Outcomes 1. Continuous BASDAI/ASDAS 
2. Binary BASDAI50, ASDAS-MI, ASAS40 
at 1yr±6m 
Binary BASDAI50/2 at 3 and 6m* Continuous SF-36, AQoL, 
HAQ-S 
 
1. Continuous BASDAI, ASDAS, spinal 
pain, BASFI, ASQoL, BASG, fatigue, 
sleep, HADS 
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2. Binary BASDAI50/2 
Methods 1. Linear mixed model stratified by 
elevated baseline CRP 
2. Logistic models 
Logistic models stratified by gender 
and TNFi 
Linear mixed model 1. Weighted GEE 
2. Weighted logistic models 
Covariates Age, symptom duration, sex, education, 
exercise, HLA-B27, classification as AS, 
BMI, baseline BASDAI (or ASDAS) and 
BASFI. 
 
Logistic models additionally included 
elevated baseline CRP. 
Age (quartile), gender, disease 
duration (tertiles), year starting 
TNFi (tertiles). Categorising 
continuous variables reduces 
control for confounding. 
 
Sensitivity analysis additionally 
adjusted for baseline BASDAI, 
BASFI, BASMI, disease duration, 
physician global. 
Age, gender, education, 
employment, comorbidity, 
use of DMARDs, NSAID and 
analgesic drugs. 
 
Separate analysis 
additionally adjusted for 
baseline BASDAI. 
None in the outcome model. IPTW 
included: age, gender, symptom 
duration, education, elevated baseline 
CRP, classification as AS, deprivation, 
BMI, comorbidities, HLA-B27, alcohol 
status; baseline BASDAI, ASDAS, spinal 
pain, BASFI, ASQoL, BASG, fatigue, 
sleep and HADS subscores. 
Results Among those with elevated baseline 
CRP, current smokers had poorer 
BASDAI (0.75 units, p=0.005) and 
ASDAS responses (0.69 units, p=0.001) 
than non-smokers. 
 
Difference not significant in the 
subgroup without elevated CRP. 
Current (OR 0.48, P<0.001) and ex-
smokers (OR 0.53, p=0.002) were 
both less likely to achieve 
BASDAI50/2 compared with non-
smokers at 3 months. 
 
Results were similar at 6 months 
and according to TNFi types and 
Coefficients for interaction 
terms were not reported, 
except that they were 
P>0.36 
Response to TNFi did not differ 
according to smoking status. 
 
Smoking status did not affect odds of 
achieving BASDAI50/2 response. 
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Current smokers had reduced odds of 
achieving BASDAI50 (OR 0.54, p=0.03), 
ASDAS-MI (OR 0.43, p=0.01) and 
ASAS40 (OR 0.43, p=0.004) compared 
with non-smokers at 1 year. Previous 
smoking did not influence response. 
gender. 
*Glintborg et al also studied time to discontinuation. 
BASDAI50, 50% reduction in BASDAI; BASDAI50/2, 50% or 2-unit reduction in BASDAI; ASDAS-MI, ASDAS major improvement; ASAS40, 40% improvement in ASAS core 
set; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; AQoL, assessment of quality of life; ASQoL, AS quality of 
life questionnaire; BASG, Bath AS Global Score; JSEQ, Jenkins Sleep Evaluation Questionnaire; HADS, Hospital Anxiety and Depression Scale; SF-12/36, 12- or 36-item 
short form health survey; HAQ-S, health assessment questionnaire for spondylitis; IPTW, inverse probability of treatment weight; IPCW, IP censoring weight. 
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